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Abstract
Background: Disease-modifying antirheumatic drug (DMARD)-free remission, the sustained absence of synovitis
after DMARD cessation, is increasingly achievable, especially in autoantibody-negative rheumatoid arthritis (RA).
However, underlying mechanisms are unknown and patient subgroups that achieve this outcome are insufficiently
characterized. We evaluated whether serological biomarkers at disease onset, as measured within the multi-
biomarker disease activity (MBDA) score, are differently expressed in RA patients who achieve sustained DMARD-
free remission.
Methods: Two hundred ninety-nine RA patients were evaluated for achievement of sustained DMARD-free remission
during a median follow-up of 4.3 years. Twelve biomarkers, as included in the MBDA score, were determined from the
serum obtained at disease onset. Patients were categorized as having a low (< 30), moderate (30–44) or high (> 44)
score. Analyses were stratified for anti-citrullinated protein antibodies (ACPA) based under the assumption that ACPA-
positive and ACPA-negative RA are different disease entities.
Results: Twenty percent achieved sustained DMARD-free remission. Overall, high MBDA scores were associated
with achieving DMARD-free remission (high vs. low HR 3.8, 95% CI 1.2–12.2). Among ACPA-negative RA patients,
moderate or high scores associated strongly with DMARD-free remission (moderate vs. low HR 9.4, 95% CI 1.2–72.
9; high vs. low HR 9.7, 95% CI 1.3–71.1). This association was independent of age and other clinical factors (high
vs. low HR 8.2, 95% CI 1.1–61.8). For ACPA-negative RA patients, the biomarkers C-reactive protein, serum amyloid
A and matrix metalloproteinase-3 were individually associated with sustained DMARD-free remission. Among
ACPA-positive RA patients, scores were not associated with DMARD-free remission.
Conclusions: ACPA-negative RA patients who achieved sustained DMARD-free remission after treatment withdrawal
were characterized by moderate to high MBDA scores at diagnosis. This is the first evidence that ACPA-negative RA
can be subdivided in clinically relevant subsets at disease onset using a protein profile.
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Background
Rheumatoid arthritis (RA) is a syndrome which presumably
consists of several disease entities. Most data have focused
on differences in RA characterized by the presence and ab-
sence of autoantibodies, in particular anti-citrullinated pro-
tein antibodies (ACPA). ACPA-positive patients have in
general a more persistent and destructive disease course
than ACPA-negative patients. The generation of different
disease subsets in seronegative patients that have a clinical
diagnosis of RA and fulfil respective classification criteria is
unsuccessful thus far [1]. Therefore, we investigated if we
could identify patients in the ACPA-negative subgroup that
have the best clinical outcome, which currently is the
achievement of sustained disease-modifying antirheumatic
drug (DMARD)-free remission.
The biological mechanisms underlying the achieve-
ment of sustained DMARD-free remission are unknown.
Additionally, it is undefined whether this outcome is po-
tentially achievable by all RA patients or whether the
ability to permanently stop DMARDs is restricted to a
set of RA patients with certain biological characteristics.
Several studies have shown that a shorter symptom dur-
ation, which is a disease phase characteristic rather than
a ‘patient characteristic’, is associated with a greater
probability of achieving sustained DMARD-free remis-
sion [2–6]. The second important factor is the absence
of ACPA [1, 2, 6]. This suggests that patients who can
achieve remission are inherently different. However, the
absence of autoantibodies only explains part of the vari-
ability in outcome, since a proportion of ACPA-positive
patients can achieve sustained DMARD-free remission
and the majority of ACPA-negative patients do not
achieve it [7]. We assumed that patients who are able to
achieve sustained DMARD-free remission are intrinsic-
ally different from patients who are unable to do so. If
this hypothesis is true, these patients might be identifi-
able by biomarkers present at disease presentation. With
respect to systemically measurable markers, C-reactive
protein (CRP) has been studied and increased levels
were associated with sustained DMARD-free remission
in one study [2], while in another study no association
was observed [8]. Other inflammatory proteins have not
been studied in relation to sustained DMARD-free
remission.
Several serological biomarkers are combined in the
multi-biomarker disease activity (MBDA) score, which is
developed to measure RA disease activity [9, 10]. The
level of the 12 biomarkers which are combined in the
MBDA score might indicate relevant pathways involved
in RA disease activity, and the combination of markers
may provide more information than markers such as the
erythrocyte sedimentation rate (ESR) or CRP alone. Sev-
eral studies have shown that higher MBDA scores mea-
sured during the disease course are predictive of
radiographic progression in the next years [11–13], al-
though there are also studies showing no association
[14–16]. It is unexplored if the serological biomarkers
included in the score are associated with an opposite,
favourable outcome, i.e. achieving sustained
DMARD-free remission.
Our ultimate aim was to identify subgroups of RA pa-
tients that are identifiable at disease presentation, for
which sustained DMARD-free remission is an achievable
outcome. We hypothesized that individual serological
markers or a combination of these is helpful to
characterize these subgroups. Therefore, we investigated
the association between the MBDA score and its compo-
nent serological markers at first presentation with RA
and the achievement of sustained DMARD-free remis-
sion. We observed that the subgroup of ACPA-negative
RA patients with a high chance of achieving sustained
DMARD-free remission can already be identified at the
time of diagnosis by the presence of a combination of
proteins.
Methods
Patients
The Leiden Early Arthritis Clinic cohort is an incep-
tion cohort that enrolls patients with clinically con-
firmed arthritis of recent onset and symptom
duration < 2 years. At baseline, questionnaires were
administered, joint counts and blood samples were
collected and patients were evaluated annually there-
after [1]. Baseline serum samples were tested for CRP
level, ESR, IgG ACPA (EliA CCP (anti-CCP2), Phadia,
Nieuwegein, the Netherlands) and IgM rheumatoid
factor (RF; in-house ELISA, as described previously
[17]). Patients did not use DMARDs or glucocorti-
coids before inclusion.
For this study, RA patients included between 2010 and
2015 were evaluated, since this is the most recent inclu-
sion period and since we have shown that sustained
DMARD-free remission is increasingly achievable with
current treatment strategies [8]. RA was stringently de-
fined by a clinical diagnosis of RA by an experienced
rheumatologist. Besides a clinical diagnosis, patients
needed to fulfil the 1987 or 2010 classification criteria
during the first year [18, 19]. Both classification criteria
were considered since ACPA-negative patients can be
misclassified by the 2010 criteria because they need > 10
involved joints to achieve 6 points. Thus, all included
RA patients had a clinical diagnosis of RA and in
addition fulfilled RA classification criteria. Patients diag-
nosed with conditions other than RA during the
follow-up were not included in this study. In the period
mentioned, 321 patients were eligible. Thirteen patients
were excluded because they did not use DMARDs dur-
ing the follow-up and 9 because measurement of an
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MBDA biomarker had failed. Thus, in total, 299 patients
were studied.
The initial treatment of RA consisted of methotrexate,
which could be combined with low-dose prednisone
bridging therapy at DMARD start. Typically, when the
first treatment failed, another conventional DMARD was
initiated or added. A biological DMARD was allowed in
patients that failed on ≥ 2 conventional DMARDs. During
the full observation period, 91% of patients ever used
methotrexate, 85% ever used other conventional
DMARDs (systemic glucocorticoids, sulfasalazine, hydro-
xychloroquine, leflunomide or azathioprine) and 20% ever
used biologicals. ACPA-positive patients more frequently
used biologicals; further details are shown in Add-
itional file 1: Table S1. According to local and inter-
national guidelines, treatment was DAS44 guided with
DMARD tapering in case of a DAS < 2.4 and intensifying
in case of a DAS ≥ 2.4 [20]. Subsequent to DMARD taper-
ing, DMARDs were stopped in case the DAS44 remained
< 2.4 and synovitis was absent at clinical joint examin-
ation. Thereafter, patients were followed on the recurrence
of synovitis or persistence of DMARD-free remission. The
study was approved by the local medical ethics committee,
and all patients signed informed consent.
Sustained DMARD-free remission
Medical files were reviewed for all patients until April
2017 to identify the occurrence of sustained
DMARD-free remission, which was defined as the
absence of synovitis (by physical examination) that
sustained after discontinuation of all DMARD therapy
(including biologics and systemic and intra-articular cor-
ticosteroids) for the entire follow-up period and must
have extended to at least 1 year after DMARD with-
drawal. The date of sustained DMARD-free remission
was defined as the date 1 year after DMARDs were
stopped. Patients who did not achieve remission were
censored at the date when the medical file was explored
or when they were lost to follow-up. One patient
achieved sustained DMARD-free remission but relapsed
during follow-up and was considered as not in
remission.
The MBDA score
Serum samples were collected at disease presentation,
before any DMARD treatment (including glucocorti-
coids) was started, and stored at − 80 °C. Crescendo Bio-
science (South San Francisco, CA, USA) measured
concentrations of 12 biomarkers using three separate
multiplex, sandwich immunoassays: CRP, IL-6 (interleu-
kin-6), SAA (serum amyloid A), TNFR1 (tumor necrosis
factor receptor superfamily member 1A), EGF (epider-
mal growth factor), VEGF-A (vascular endothelial
growth factor-A), VCAM-1 (vascular cell adhesion
molecule-1), MMP-1 (matrix metalloproteinase-1),
MMP-3 (matrix metalloproteinase-3), YKL-40 (human
cartilage glycoprotein-39), resistin and leptin. Measure-
ments were performed blinded to clinical data and out-
come. The biomarkers were studied individually and in
combination by using a previously specified algorithm to
calculate the MBDA score, ranging on a scale from 1 to
100 [9, 10, 21]. This MBDA algorithm was developed to
measure disease activity with DAS28-CRP as reference.
For analyses, patients were categorized according to pre-
viously established thresholds in categories of low (< 30),
moderate (30–44) and high (> 44) MBDA score [10]. Al-
though we used the MBDA score for a purpose different
than measuring disease activity, we used the same
cut-off points for categorization.
Statistical analyses
Kaplan-Meier analysis was used to estimate rates of
achieving sustained DMARD-free remission with MBDA
category and the 12 individual biomarkers as grouping
factors. For the latter analyses, patients were categorized
into tertiles based on the biomarker levels to create
three groups of equal size. Univariable Cox proportional
hazards regression analyses were used to assess the asso-
ciation between baseline characteristics and the achieve-
ment of sustained DMARD-free remission. Baseline
variables with a p value < 0.10 were included in a multi-
variable analysis to assess the independent relation be-
tween the serological markers and the achievement of
sustained DMARD-free remission. Because achieving
sustained DMARD-free remission is mostly confined to
ACPA-negative RA and since we aimed to search for
subgroups within ACPA-negative and ACPA-positive
RA, analyses were stratified for the presence of ACPA.
SPSS version 23.0 (IBM) was used. p values < 0.05 were
considered significant.
Results
Patient characteristics
Baseline characteristics of the 299 RA patients are pre-
sented in Table 1. The median symptom duration at first
presentation was 15 weeks (interquartile range (IQR) 8–
32) and, similar to other early arthritis cohorts, 53% of
patients were ACPA positive [22, 23].
Development of sustained DMARD-free remission and
distribution of MBDA scores
The median follow-up duration was 4.3 years (IQR 4.0–
4.7). Sustained DMARD-free remission was achieved in
20% (59/299) of RA patients after a median follow-up of
2.9 years (IQR 2.2–4.0). Sustained DMARD-free remis-
sion was achieved by 7% (11/158) of ACPA-positive pa-
tients and 34% (48/141) of ACPA-negative patients.
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A combination of serological markers as reflected by
MBDA scores associated with sustained DMARD-free
remission within ACPA-negative RA
First, the association between the achievement of sus-
tained DMARD-free remission during follow-up and the
MBDA score at disease onset was evaluated in all RA pa-
tients (Fig. 1a). With patients with low MBDA scores as
reference, patients with moderate MBDA scores had an
increased probability on the development of sustained
DMARD-free remission (hazard ratio (HR) 3.42, 95% con-
fidence interval (CI) 0.97–12.02). A similar increased
probability was observed for patients with high MBDA
scores (HR 3.79, 95% CI 1.18–12.22). Next, patients were
stratified for the presence of ACPA (Fig. 1b, c). For
ACPA-positive RA patients, the baseline MBDA category
was not associated with achieving sustained DMARD-free
remission (moderate vs. low HR 0.75, 95% CI 0.10–8.19;
high vs. low HR 0.89, 95% CI 0.19–4.31). By contrast,
among ACPA-negative RA patients, moderate or high
MBDA scores were strongly associated with achieving
sustained DMARD-free remission (moderate vs. low HR
9.40, 95% CI 1.21–72.85; high vs. low HR 9.73 95% CI
1.33–71.10). Sustained DMARD-free remission was al-
most absent in the ACPA-negative group with low MBDA
scores (only one patient in this group achieved remission
after 6 years follow-up), whereas sustained DMARD-free
remission was achieved by 38% of the ACPA-negative pa-
tients with moderate or high MBDA scores. The HR for
achieving remission was 9.65 (95% CI 1.33–70.04) when
ACPA-negative RA patients with either moderate or high
MBDA scores were compared with patients with low
MBDA scores. Thus, only for ACPA-negative RA patients,
a combination of serological markers at diagnosis,
reflected by the MBDA score, was associated with
achievement of sustained DMARD-free remission.
A combination of serological markers associated with
sustained DMARD-free remission, independent of clinical
factors
Next, we investigated whether the association between
baseline MBDA score and sustained DMARD-free remis-
sion within ACPA-negative patients was independent of
clinical characteristics. Of the clinical baseline characteris-
tics, age at disease onset, the 66-swollen joint count and
the presence of RF associated with sustained DMARD-free
remission, with a p value < 0.10 in ACPA-negative RA;
these characteristics were included in a multivariable ana-
lysis (Table 2). In this analysis, the MBDA category was
associated with sustained DMARD-free remission, inde-
pendent of these three factors, with moderate vs. low HR
6.96 (95% CI 0.88–55.31) and high vs. low HR 8.19 (95% CI
1.09–61.78) (Table 2).
Among ACPA-negative RA patients, higher CRP, SAA and
MMP-3 levels associated with achieving sustained
DMARD-free remission
Next, it was studied whether the observed association
for ACPA-negative RA patients was driven by a subset
Table 1 Baseline characteristics of all RA patients and of subgroups of ACPA-positive and ACPA-negative patients
All RA patients (n = 299) ACPA-positive RA patients (n = 158) ACPA-negative RA patients (n = 141)
Age in years, mean (SD) 57 (14) 54 (14) 60 (14)
Female, n (%) 198 (66) 105 (66) 93 (66)
Symptom duration in weeks, median (IQR) 15 (8–32) 18 (9–38) 12 (5–26)
(Sub)acute symptom onset, n (%) 95 (34) 39 (27) 56 (43)
66-SJC, median (IQR) 6 (3–11) 5 (2–8) 8 (3–12)
68-TJC, median (IQR) 9 (4–15) 7 (4–13) 10 (4–18)
RF positivity, n (%) 183 (61) 134 (85) 49 (35)
ESR (mm/h), median (IQR) 28 (14–41) 28 (14–41) 28 (11–41)
CRP (μg/mL), median (IQR) 10 (3–23) 8 (3–18) 12 (3–30)
PTGA (0–100), median (IQR) 70 (50–80) 70 (45–80) 70 (60–80)
DAS44, median (IQR) 2.9 (2.4–3.4) 2.8 (2.3–3.3) 3.0 (2.5–3.7)
MBDA category
Low (< 30), n (%) 43 (14) 26 (16) 17 (12)
Moderate (30–44), n (%) 64 (21) 35 (22) 29 (21)
High (> 44), n (%) 192 (64) 97 (61) 95 (67)
Some data were missing as follows: symptom duration n = 4, (sub)acute symptom onset n = 23, 66-SJC n = 19, 68-TJC n = 17, ESR n = 3, PTGA n = 50 , DAS44 n = 20
and CRP n = 1
Symptom duration, time between symptom onset and inclusion in cohort; (sub)acute symptom onset, prompt onset of symptoms (< 1 week); SD, standard
deviation; IQR, interquartile range; SJC, 66-swollen joint count; TJC, 68-tender joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PTGA,
patient global assessment; DAS, disease activity score; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; RA, rheumatoid arthritis; MBDA, multi-
biomarker disease activity
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of markers of the MBDA score. Therefore, the associ-
ation between the level of the 12 individual bio-
markers included in the MBDA score and the
achievement of sustained DMARD-free remission was
determined for ACPA-negative RA patients
(Additional file 1: Figure S1). Of the individual bio-
markers, higher CRP, SAA and MMP-3 levels at dis-
ease onset were associated with achieving sustained
DMARD-free remission during the follow-up. Pa-
tients with CRP levels 7–39 μg/mL (second tertile)
had a significantly increased probability on achieving
sustained DMARD-free remission compared with pa-
tients with CRP levels < 7 μg/mL (lowest tertile) (HR
3.43, 95% CI 1.62–7.27), and for patients with CRP
levels ≥ 39 μg/mL (highest tertile), a similar trend
was observed (HR 2.12, 95% CI 0.96–4.70). In
addition, patients with MMP-3 levels ≥ 60 ng/mL
(highest tertile) had a significantly increased
probability on the development of sustained
DMARD-free remission compared with patients with
MMP-3 levels ≤ 28 ng/mL (lowest tertile) (HR 2.18,
95% CI 1.06–4.48). SAA levels were also associated
with achieving DMARD-free sustained remission. Pa-
tients with SAA levels ≥ 26 μg/mL (highest tertile) or
3–26 μg/mL (second tertile) had a significantly in-
creased probability on the development of sustained
DMARD-free remission compared with patients with
SAA levels ≤ 3 μg/mL (lowest tertile) (HR 2.87, 95%
CI 1.28–6.43 and HR 3.03, 95% CI 1.39–6.63, re-
spectively). The other biomarkers were not individu-
ally associated with the achievement of sustained
DMARD-free remission.
Fig. 1 Kaplan-Meier plot showing achievement of sustained DMARD-free remission by category of MBDA score for all RA patients (a), ACPA-positive RA
patients (b) and ACPA-negative (c) RA patients. Vertical lines indicate that a patient is censored. The numbers below the figures denote the number of
patients at risk in each group. Visual representation of the data was restricted to 5 years follow-up since thereafter the number of patients was small.
DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; ACPA, anti-citrullinated protein antibodies; MBDA, multi-biomarker disease activity
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Clinical characteristics at disease presentation of ACPA-
negative RA patients with an elevated MBDA score
Finally, as ACPA-negative RA patients with a high
probability on achieving sustained DMARD-free
remission were identifiable by a protein profile that
reflected high disease activity at the time of diagnosis,
we evaluated whether these patients also had differ-
ences in clinical characteristics compared with those
presenting with low MBDA scores. ACPA-negative
patients with a high MBDA score more often had a
subacute onset of symptoms (vs. gradual or
intermittent onset) (Table 3). ACPA-negative patients
with a moderate or high MBDA score were approxi-
mately 10 years older and had higher acute phase
reactants at the first presentation, compared with
ACPA-negative patients with a low MBDA score
(Table 3). These associations with clinical characteris-
tics at diagnosis suggest that subgroups of
ACPA-negative RA, differentiated based on serological
biomarkers, not only have differences in long-term
outcome but also differ already at disease
presentation.
Table 2 Association between the MBDA score and achieving sustained DMARD-free remission over time within ACPA-negative RA
patients
ACPA-negative RA patients
Univariable analyses Multivariable analysis
Without MBDA
Multivariable analysis
Including MBDA
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
MBDA score
Low Reference Reference
Moderate 9.40 (1.21–72.85) 0.032 6.96 (0.88–55.31) 0.067
High 9.73 (1.33–71.10) 0.025 8.19 (1.09–61.78) 0.041
Age at disease onset, per year 1.04 (1.02–1.07) 0.001 1.03 (1.01–1.06) 0.006 1.03 (1.00–1.06) 0.036
Female 1.43 (0.80–2.55) 0.23
Symptom duration > 12 weeks 0.96 (0.54–1.70) 0.89
(Sub)acute symptom onset 0.93 (0.51–1.69) 0.81
66-SJC, per joint 1.04 (0.99–1.08) 0.099 1.03 (0.99–1.08) 0.15 1.02 (0.98–1.06) 0.40
68-TJC, per joint 0.99 (0.96–1.02) 0.56
ESR, per mm/h 1.01 (1.00–1.02) 0.17
CRP, per µg/mL 1.00 (1.00–1.01) 0.36
RF positivity 0.57 (0.29–1.09) 0.088 0.84 (0.42–1.66) 0.61 0.78 (0.39–1.58) 0.50
Of the 141 ACPA-negative RA patients, 48 achieved sustained DMARD-free remission. Baseline variables with a p value < 0.10 in univariable analyses were
included in a multivariable analysis to assess the independent relation between baseline variables and sustained DMARD-free remission
Table 3 Baseline characteristics of ACPA-negative RA patients per MBDA category
MBDA category p
value< 30 (n = 17) 30–44 (n = 29) > 44 (n = 95)
Age in years, mean (SD) 48 (16) 60 (13) 62 (14) < 0.001
Female, n (%) 13 (76) 22 (76) 58 (61) 0.21
Symptom duration in weeks, median (IQR) 26 (8–41) 12 (4–25) 12 (5–22) 0.13
(Sub)acute symptom onset, n (%) 3 (20) 7 (26) 46 (52) 0.01
66-SJC, median (IQR) 3 (2–7) 6 (3–13) 9 (3–13) 0.08
68-TJC, median (IQR) 12 (9–19) 11 (5–21) 9 (4–17) 0.23
RF positivity, n (%) 7 (41) 9 (31) 33 (35) 0.78
ESR (mm/h), median (IQR) 9 (4–14) 14 (6–33) 33 (19–48) < 0.001
CRP (µg/mL), median (IQR) 3 (3–3) 3 (3–4) 22 (11–44) < 0.001
Characteristics of ACPA-negative RA patients with low, moderate or high MBDA score were compared with one-way ANOVA, chi-square test and Kruskal-Wallis
test, as appropriate
Symptom duration, time between symptom onset and inclusion in cohort; (sub)acute symptom onset, prompt onset of symptoms (< 1 week); SD, standard
deviation; IQR, interquartile range; SJC, 66-swollen joint count; TJC, 68-tender joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF,
rheumatoid factor; ACPA, anti-citrullinated protein antibodies; RA, rheumatoid arthritis; MBDA, multi-biomarker disease activity
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Discussion
This is the first study showing that ACPA-negative RA
patients with a high likelihood of achieving sustained
DMARD-free remission during follow-up were identifi-
able at baseline by a combination of serological markers.
This association with sustained DMARD-free remission
was independent of clinical baseline characteristics. Fur-
thermore, the ACPA-negative subgroup with a high like-
lihood of achieving sustained DMARD-free remission
showed some differences in clinical characteristics as
they were older (mean ≥ 60 years) and more often had a
(sub)acute symptom onset. Together, this suggests that a
combination of serological biomarkers is helpful in iden-
tifying subgroups of ACPA-negative RA patients at dis-
ease presentation that differ in baseline characteristics
and in their ability to maintain clinical remission after
DMARD withdrawal.
Based on differences in genetic and environmental risk
factors and in outcome, it is generally accepted that
ACPA-positive and ACPA-negative RA are different RA
subsets. In the past, we attempted to distinguish sub-
groups within the group of ACPA-negative RA patients
based on only clinical characteristics at disease onset;
this did not result in clinically distinguishable subgroups
[24]. The current data suggest that a subdivision is pos-
sible with serological markers and that, starting from
this subdivision, the identified subgroups had some
slight differences in clinical characteristics as
ACPA-negative RA patients with moderate or high sero-
logic scores at disease onset were older, had more often
a (sub)acute onset of symptoms and appeared to have
greater inflammatory burden (reflected by higher levels
of inflammatory proteins and a tendency towards more
swollen joints). Thirty-eight percent of these patients
were able to permanently stop DMARDs after a rela-
tively short period of treatment, since DMARD-free re-
mission was achieved after a median disease duration of
2.9 years, which means that DMARDs were stopped after
median 1.9 years. Thus, the identified subgroup of
ACPA-negative patients was older at disease onset and
had more often a prompt onset of symptoms with more
severe inflammation but a relative short-term necessity
of DMARD treatment. Further studies are needed to
confirm these findings.
It is unlikely that ACPA-negative RA patients were
misclassified as having RA because patients that dur-
ing the first year of follow-up were diagnosed with
conditions other than RA (e.g. inflammatory osteo-
arthritis and reactive arthritis) were not included in
this study. Also, patients that achieved spontaneous
remission, i.e. without the use of DMARDs, were ex-
cluded. Patients studied here had a clinical diagnosis
of RA and fulfilled classification criteria. In the
current taxonomy, these patients are called RA
patients. However, our data support the notion that
subgroups can be identified within ACPA-negative
RA.
A study of established RA patients with a median dis-
ease duration of 5 years, who were in sustained remis-
sion, showed that high MBDA scores during DMARD
treatment and prior to treatment reduction were associ-
ated with increased risk of relapses in patients who re-
duced, and in some cases, stopped, all their DMARD
treatments [25]. This might be reflective of subclinical
disease activity despite treatment and is conceptually
very different from our data. In this study, the MBDA
score was used to monitor disease activity, the aim for
which the score was derived. In our data, we had a dif-
ferent aim for which measurements were performed in
RA patients with very short symptom duration and be-
fore any DMARDs were initiated.
High MBDA scores have been associated with radio-
graphic progression in several studies (although most
did adjust but not stratify for ACPA) [11–13, 26]. In our
study, performed at disease presentation, high MBDA
scores strongly associated with a favourable outcome in
ACPA-negative RA. This contrasts with the previous
findings, but measurements in these studies were done
in patients with a disease duration of several years and
the studied outcomes were also different.
Our study was focused on achieving sustained
DMARD-free remission. Within the group of
ACPA-negative RA patients, patients with low MBDA
score infrequently achieved this favourable outcome.
Numerically, this group was relatively small (12% of
ACPA-negative RA patients). Furthermore, this group
resembled the ACPA-positive group of RA patients that
also infrequently achieved DMARD-free remission. This
ACPA-negative subgroup may be interesting for studies
on (novel) autoantibody reactivities, as it is speculated
that a ‘serological gap’ exists, meaning that part of
ACPA-negative patients harbour unmeasured autoanti-
bodies [27]. Moreover, our data revealed that sustained
DMARD-free remission is a feasible outcome in about
half of the ACPA-negative patients with moderate or
high MBDA score.
A limitation is that although rheumatologists at our
outpatient clinic are encouraged to try to taper and stop
DMARDs in case of DAS remission, patients and rheu-
matologists were not forced to stop DMARDs if this was
felt inappropriate and we did not record how often
DMARD tapering was not done despite the presence of
DAS remission and the absence of swollen joints. Conse-
quently, the proportion of patients able to achieve sus-
tained DMARD-free remission might be underestimated.
It is particularly conceivable that either physicians or pa-
tients were reluctant with lowering or stopping medica-
tion in the presence of a positive ACPA test.
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Another limitation is that the follow-up duration of
some patients might have been insufficient to detect flares
occurring years after the absence of synovitis, as this may
occur after discharge from the outpatient clinic. For this
study, patients needed to be in sustained DMARD-free re-
mission for at least 1 year and patients were instructed to
return to the outpatient clinic when symptoms recurred,
an instruction that is facilitated by the presence of early
arthritis recognition clinics and the fact that we are the
only referral center in the region [28]. A final limitation is
that the number of seronegative patients with low MBDA
score was relatively small and therefore (multivariable)
analyses within the ACPA-negative subgroup were of lim-
ited power resulting in wide confidence intervals of esti-
mated hazard ratios. In addition, resampling methods to
show robustness of the data were not performed. There-
fore, validation of our results in another early RA cohort
is needed.
Remission in this study was defined as the persistent
absence of synovitis after DMARD cessation and thus
was physician centred. Since synovitis needed to be per-
sistently absent over time, this outcome is different from
frequently used remission definitions that are used on
single time points. Importantly, we have shown that
patients who achieve sustained DMARD-free remission
have normalization of functional status and of
patient-reported outcomes, underlining that it is the best
possible long-term outcome [1].
The MBDA test comprised of serum levels of 12 pro-
teins which were also evaluated separately. Of the differ-
ent markers, CRP, SAA and MMP-3 were associated
with achieving sustained DMARD-free remission. SAA
is a protein linked to the acute phase response and is a
sensitive indicator of RA disease activity [29, 30].
MMP-3 is a proteinase considered to contribute to car-
tilage degradation in RA. Its levels have been associated
with radiographic progression and also with disease ac-
tivity and inflammation [31–36]. As the MBDA score
was not designed to assess which patients might achieve
DMARD-free remission, it is presumable that proteins
other than the 12 that were studied here are also differ-
ently expressed in subgroups of ACPA-negative RA. Fur-
ther studies are needed to better characterize this
subgroup serologically. Additionally, biologic studies are
needed to identify pathways that are relevant for the de-
velopment of this subgroup of RA patients.
Conclusions
In conclusion, ACPA-negative RA patients who achieved
sustained DMARD-free remission during follow-up were
characterized by differences in protein expression at dis-
ease presentation. This is the first evidence that
ACPA-negative RA can be subdivided at disease onset in
clinically relevant subgroups with differences in the
likelihood of achieving and maintaining clinical remis-
sion after treatment withdrawal.
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